<DOC>
	<DOC>NCT01736241</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3053102 in healthy participants. The study will also investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. The study is expected to last approximately 8 weeks for each participant (up to 4 weeks from the screening visit to the administration of study drug and an additional 4 weeks of follow up).</brief_summary>
	<brief_title>A Study of LY3053102 in Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Normal blood pressure Female participants are not of childbearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause Have a body mass index (BMI) of 18.5 to 40.0 kilograms per square meter (kg/m^2), inclusive, at screening Have known allergies to LY3053102 or related compounds Have a history of significant disease that may affect the actions of drugs or may pose a risk when taking the study medication Have a history of developing allergies, asthma, severe drug allergies (symptoms including, but not limited to, itching, red rashes, sores on the skin, scaling and shedding of skin), allergies or reactions to more than one drug, or have had bad reactions to skin creams containing corticosteroids Heavy smokers (more than 10 cigarettes a day)</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>